SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRE (medco research)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Scott H. Davis who wrote (122)9/21/1998 9:56:00 AM
From: Invest2Ride   of 192
 
MRE has a number of adenosine receptor agonists/antagonists in the FDA pipeline. They may have been turned down for approval for one of these. Usually, this means that their clinical trial data is not as comprehensive or compelling as FDA wishes it to be. They will have to decide whether the trend seen in existing data is compelling enough to expend the money for more trials.

Do you remember the product?

I am fairly familiar with the adenosine literature. I am researching whether adenosine receptors play a role in wound healing. I'm developing an in vitro model system that can be used in Phase I-III clinical trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News